GALNT14 regulates ferroptosis and apoptosis of ovarian cancer through the EGFR/mTOR pathway

Future Oncol. 2022 Jan;18(2):149-161. doi: 10.2217/fon-2021-0883. Epub 2021 Oct 13.

Abstract

Background: Chemoresistance usually occurs in ovarian cancer. We aimed to explore the mechanisms of chemoresistance. Methods: Western blotting assay was used to detect the expression of GALNT14. Further cell function experiments were performed to investigate the effect of GALNT14 in ovarian cancer. Results: GALNT14 is significantly upregulated in ovarian cancer. Downregulation of GALNT14 significantly inhibits both apoptosis and ferroptosis of ovarian cancer cells. A further mechanism assay illustrated that downregulation of GALNT14 suppresses the activity of the mTOR pathway through modifying O-glycosylation of EGFR. Finally, an additive effect promoting cell death occurs with a combination of an mTOR inhibitor and cisplatin. Conclusion: Our study might provide a promising method to overcome cisplatin resistance for patients with ovarian cancer.

Keywords: EGFR; GALNT14; chemotherapy resistance; glycosylation; protein stability.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Apoptosis / drug effects
  • Apoptosis / genetics
  • Cell Line, Tumor
  • Cisplatin / pharmacology*
  • Cisplatin / therapeutic use
  • Drug Resistance, Neoplasm / drug effects
  • Drug Resistance, Neoplasm / genetics*
  • ErbB Receptors / metabolism
  • Female
  • Ferroptosis / drug effects
  • Ferroptosis / genetics
  • Gene Expression Regulation, Neoplastic
  • Glycosylation / drug effects
  • Humans
  • Middle Aged
  • N-Acetylgalactosaminyltransferases / metabolism*
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / genetics
  • Ovarian Neoplasms / pathology
  • Ovary / pathology
  • Signal Transduction / drug effects
  • Signal Transduction / genetics
  • Sirolimus / analogs & derivatives
  • Sirolimus / pharmacology
  • Sirolimus / therapeutic use
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • TOR Serine-Threonine Kinases / metabolism
  • Up-Regulation

Substances

  • temsirolimus
  • N-Acetylgalactosaminyltransferases
  • UDP-N-acetyl-D-galactosamine polypeptide N-acetylgalactosaminyltransferase 14, human
  • MTOR protein, human
  • EGFR protein, human
  • ErbB Receptors
  • TOR Serine-Threonine Kinases
  • Cisplatin
  • Sirolimus